VivoSeq
Oncology

Advanced or Metastatic Solid Tumor

3

Pipeline Programs↗

8

Active Trials↗

7

Companies Involved↗

Advanced or Metastatic Solid Tumor is an early-stage landscape with 3 programs across 7 companies. The most active players are AstraZeneca, Taiho Oncology, Inc., Sichuan Baili Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

3 programs

Phase 1Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

0 programs

PreclinicalS

Sichuan Baili Pharmaceutical Co., Ltd.

0 programs

PreclinicalK

Karyopharm Therapeutics Inc

0 programs

PreclinicalGilead logo

Gilead

0 programs

PreclinicalA

Affini-T Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

Saruparib

AstraZeneca

[14c]-AZD5305 Microtracer

AstraZeneca

[14c]-AZD5305 (therapeutic Dose)

AstraZeneca

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

16

clinical trials

Recruiting5 · 31%
Terminated4 · 25%
Completed4 · 25%
Not yet recruiting2 · 13%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05194982·570 enrolled
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Recruiting·YYuhan Corporation·Phase 1/2·NCT05523947·147 enrolled
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Recruiting·KKangabio AUSTRALIA LTD PTY·Phase 1·NCT07260305·57 enrolled
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Recruiting·Gilead logoGilead·Phase 1·NCT04617522·30 enrolled
A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT06713369·8 enrolled
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Active, not recruiting·AAffini-T Therapeutics, Inc.·Phase 1/2·NCT06105021·100 enrolled
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
Not yet recruiting·EEvopoint Biosciences Inc.·Phase 1/2·NCT07327294·150 enrolled
A Phase I/Ⅱa Study of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Not yet recruiting·HHutchmed·Phase 1/2·NCT07396584·186 enrolled
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Completed·KKaryopharm Therapeutics Inc·Phase 1·NCT01607905·192 enrolled
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Completed·AAutotelicbio·Phase 1·NCT04862767·9 enrolled
Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor
Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003755·40 enrolled
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
Completed·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05830539·68 enrolled
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
Terminated·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 1·NCT04586270·47 enrolled
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Terminated·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 1·NCT04982926·29 enrolled
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Terminated·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT04178460·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)